Zhang, Bixiang

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

H19 promotes HCC bone metastasis through reducing osteoprotegerin expression in a protein phosphatase 1 catalytic subunit alpha/p38 mitogen-activated protein kinase-dependent manner and sponging microRNA 200b-3p

Huang, Z., Chu, L., Liang, J., Tan, X., Wang, Y., Wen, J., Chen, J., Wu, Y., Liu, S., Liao, J., et al. (2021) · Hepatology

Cancer-related molecular mechanisms researchBone Metabolism and Diseases

Cited by 82

Liquid-liquid phase separation in Alzheimer’s disease

Fu, Q., Zhang, B., Chen, X., & Chu, L. (2024) · Journal of Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 33

Bone lesion-derived extracellular vesicles fuel prometastatic cascades in hepatocellular carcinoma by transferring ALKBH5-targeting miR-3190-5p

Han, S., Xue, L., Wei, Y., Yong, T., Jia, W., Qi, Y., Luo, Y., Liang, J., Wen, J., Bie, N., et al. (2023) · Advanced Science

Extracellular vesicles in diseaseMicroRNA in disease regulation

Cited by 24